Xeris Biopharma Holdings (XERS) Cash & Current Investments (2020 - 2026)

Xeris Biopharma Holdings (XERS) has 7 years of Cash & Current Investments data on file, last reported at $111.8 million in Q1 2026.

• Quarterly Cash & Current Investments rose 91.22% year-over-year to $111.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $111.8 million (up 91.22% YoY) and the FY2025 annual result came in at $111.0 million, up 55.04% from the prior year.
• Cash & Current Investments grew to $111.8 million in Q1 2026, from $111.0 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $132.1 million in Q1 2022 to a low of $58.4 million in Q1 2025.
• A 5-year average of $88.9 million and a median of $87.4 million in 2024 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2023 — Cash & Current Investments tumbled 40.6% — and 2026, when it soared 91.22%.
• Tracing XERS's Cash & Current Investments over 5 years: stood at $122.0 million in 2022, then slumped by 40.6% to $72.5 million in 2023, then retreated by 1.15% to $71.6 million in 2024, then surged by 55.04% to $111.0 million in 2025, then increased by 0.64% to $111.8 million in 2026.
• The last three Cash & Current Investments figures came in at $111.8 million (Q1 2026), $111.0 million (Q4 2025), and $91.6 million (Q3 2025), per Business Quant data.